It’s time for the next Virtual Pitch Feedback Session for Digital Health Start-ups with Angelika Vlachou, Partner HTGF Berlin, Jakob Lilienweiss, Investment Analyst, HTGF, and our guest Dr. Alexander Ehlgen, Investment Manager at Boehringer Ingelheim Venture Fund.
Are you a founder, entrepreneur, or researcher who wants to start a business? Then join our 1:1 pitch session and get early feedback from Jakob and Alexander on your 5-minute pitch.
You can ask any questions you might have, such as:
- What information is most relevant for an investor?
- How to present information appropriately?
- How to improve your presentation skills
.. and any other questions you might have on your mind!
Angelika holds a PhD in biology and has been investing venture capital in biotech, pharma, and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions, and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential.
Jakob holds a Bachelor’s degree in Economics and has completed a double Master’s degree in Management, specializing in Innovation and Strategy. His first contact with venture capital was during his Master’s thesis on ‘Corporate Venture Capital (CVC) investment relationships from the perspective of Tech-oriented Start-ups’, where he analyzed the motivations, concerns, and protection mechanisms for start-ups when accepting CVC investments. He joined High-Tech Gründerfonds in 2021.
Our special guest is CVC expert Alexander Ehlgen. He joined Boehringer Ingelheim Venture Fund in 2019. He is responsible for Digital Healthcare and Therapeutics investments in Europe and Israel. Alexander is a physician, who received his medical degree from the University of Bonn, Germany. He worked at a biotech start-up and major pharmaceutical companies in a variety of roles in clinical drug development.
We look forward to meeting you!